REPORTING FROM ACTRIMS
Americas Committee for Treatment and Research in Multiple Sclerosis
West Palm Beach, Florida
SATURDAY, FEBRUARY 29
© 2020, Consortium of Multiple Sclerosis Centers. Published by Delaware Media Group, LLC. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this publication are those of the presenters and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, or Bristol-Myers Squibb.
Research by Patrizia Casaccia, MD, PhD, Chief of the Center of Excellence for Myelin Repair at the Friedman Brain Institute, Icahn Mount Sinai School of Medicine, New York City, focuses on epigenetics, or change in genes that do not affect DNA sequencing.WEST PALM BEACH, FL — What can we learn about multiple sclerosis (MS) by looking at epigenetic changes in brain and immune cells? Patrizia Casaccia, MD, PhD, addressed this issue in her talk on Friday, February 28, at the 2020 ACTRIMS Forum. "A growing body of evidence suggests that epigenetic changes play an important role in MS pathology and could be potential therapeutic targets," she suggested.